SEC Form 4 · accession 0001209191-18-039681
GLOBUS MEDICAL INC · GMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Schwartz
Officer — Senior VP and General Counsel
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001237831
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 25, 2018 | M | 10,000 | $24.98 | A | 10,000 | D | |
| Class A Common StockF2 | Jun 25, 2018 | S | 8,444 | $53.638 | D | 1,556 | D | |
| Class A Common StockF3 | Jun 25, 2018 | S | 1,556 | $54.594 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)F4 | $24.98 | Jun 25, 2018 | M | 10,000 | D | — | Apr 28, 2026 | Class A Common Stock | 10,000 | 41,000 | D |
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan executed by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.24 to $54.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.29 to $54.81, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4These options were included in a grant of 75,000 options that was granted on May 3, 2016, and which vests over a four-year period with one-fourth (1/4) of the options granted vesting on April 28, 2017, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.